Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Phase 3 Age-Related Macular Degeneration Trials

9 Phase 3 trials for Age-Related Macular Degeneration. Phase 3 trials are the final stage of testing before a treatment can be submitted for FDA approval.

What is a Phase 3 trial?

Phase 3 clinical trials study a treatment in large groups (hundreds to thousands of people) to confirm its effectiveness, monitor side effects, and compare it to standard treatments. These trials are the last major step before the FDA considers approving a new treatment.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
RECRUITINGPhase 3NCT05407636

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD...

Sponsor: AbbVieEnrolling: 66020 locations
RECRUITINGPhase 3NCT07064759

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related...

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration

Sponsor: 4D Molecular TherapeuticsEnrolling: 48020 locations
RECRUITINGPhase 3NCT06856577

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular...

This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with...

Sponsor: Adverum Biotechnologies, Inc.Enrolling: 28420 locations
RECRUITINGPhase 3NCT06996080

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema...

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)

Sponsor: Kodiak Sciences IncEnrolling: 15020 locations
RECRUITINGPhase 3NCT05562947

A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in...

This study will evaluate the efficacy, safety, and PK of ranibizumab 100 milligrams per milliliter (mg/mL) delivered every 24 weeks (Q24W) via the PDS implant compared with...

Sponsor: Hoffmann-La RocheEnrolling: 6816 locations
RECRUITINGPhase 3NCT06165068

Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study

The aim of this clinical trial is to evaluate the effect of low doses of antiplatelet medications (aspirin 81 mg/day or clopidogrel 75 mg/day) with or without a combination of...

Sponsor: Navamindradhiraj UniversityEnrolling: 1741 location
RECRUITINGPhase 3NCT07461441

Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal...

To evaluate the Efficacy of a personalized treat-and-extend regimen of faricimab for treatment-naive polypoidal choroidal vasculopathy

Sponsor: Yeungnam University College of MedicineEnrolling: 501 location
RECRUITINGPhase 3NCT06990399

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema...

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)

Sponsor: Kodiak Sciences IncEnrolling: 15020 locations
RECRUITINGPhase 3NCT06305416

A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema

Macular edema in diabetes, defined as retinal thickening within two disc diameters of the center of the macula, results from retinal microvascular changes that compromise the...

Sponsor: Incepta Pharmaceuticals LtdEnrolling: 701 location